An observational study in Fibromyalgia and Cognition, sponsored by Zülal TATAR. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Zülal TATAR · Observational
Among 195 studies in Fibromyalgia with a site in Turkey — 51 open to participants now, 55 under way, none of them phase 3. Fibromyalgia · Turkey.
Among the 195 studies in Fibromyalgia with a site in Turkey, this one is the 83rd largest by planned enrollment of the 91 observational ones that give a count, is one of 25 that started in 2026, is one of 91 observational ones, reaches primary completion later than 49 of the 54 other live ones, and was the 181st registered.
1,243 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →51 of the 195 studies in Fibromyalgia with a site in Turkey are open now. Recruiting first, the newest first:
Karabuk University · Sites in Turkey
Ages 18–65 · Women only · Healthy volunteers
Artvin Coruh University · Sites in Turkey
Ages 18+
Artvin Coruh University · Sites in Turkey
Ages 18+
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · Sites in Turkey
Ages 18–65 · Women only
Ankara Yildirim Beyazıt University · Sites in Turkey
Ages 18–65 · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 160 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 96 (60%) stop at 75 or younger; 14 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 65 Years · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
195 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 41 is below the median of 100 across 279 observational studies indexed under Fibromyalgia.
Median enrollment 52 across the 104 interventional studies, 100 across the 91 observational. Of the 126 that completed or were terminated, 3 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 195 have an industry lead sponsor. The 10 most frequent:
Zülal TATAR is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Zülal TATAR has 1 study filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
19 of the studies in Fibromyalgia with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07416097Izmir Democracy UniversityComparison of Multidimensional Parameters in Women With Fibromyalgia and Healthy Controls | 2026-11-15 |
| NCT07261696Nigde Omer Halisdemir UniversityThe Effects of Inspiratory Muscle Training Female Patients With Fibromyalgia | 2026-12-05 |
| NCT07403929Hacettepe UniversityThe Effect of Fermented Grape Juice Consumption on Fibromyalgia Patients | 2026-12-15 |
| NCT07326163Bilecik Seyh Edebali UniversitesiThe Effect of Peppermint Oil Aromatherapy on Pain, Functional Capacity and Cost in Fibromyalgia Patients | 2026-12-30 |
| NCT07878286Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyThe Role of Interoceptive Sensitivity in Central Sensitization Symptom Severity in Fibromyalgia | 2027-01-15 |
Among the 195 studies in Fibromyalgia with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study was to identify factors associated with cognitive skills in female patients with fibromyalgia.
At least 41 female fibromyalgia patients aged 18-65 years who are followed by Pamukkale University Rheumatology Clinic, diagnosed according to the 2011 American Rheumatology Association Fibromyalgia classification criteria, and who meet the inclusion criteria will be included in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dynamic Loewenstein Occupational Therapy Cognitive Assessment (DLOTCA)
DLOTCA assesses the basic cognitive skills of individuals aged 18-69 years using 28 subtests across 7 cognitive domains (Awareness, Orientation, Spatial Perception, Visual Perception, Visual-Motor Structuring, Application, and Thinking Processes) (13). Each subtest has 3 scoring stages: First stage: Pre-mediation scoring (1 point indicates the worst performance). Second stage: Mediation score (a high score (4 or 5) indicates poor performance). Third stage: Post-mediation scoring (1 point indicates the worst performance).
Time frame: At baseline (Day 1)
Fibromyalgia Impact Questionnaire
This physical impact scale, administered to patients, was developed by Burchardt et al. to measure functional status in fibromyalgia patients. The scale primarily measures 10 separate characteristics: physical function, well-being, inability to work, difficulty at work, pain, fatigue, morning fatigue, stiffness, anxiety, and depression. Except for well-being, lower scores indicate improvement or less severe impact from the disease. Each subcategory can have a maximum score of 10, resulting in a total maximum score of 100.
Time frame: At Baseline (Day 1)
Pressure Pain Threshold Measurements
Pressure pain threshold measurements will be assessed using a pressure algometer, a gun-shaped apparatus with a 1-cm² rigid rubber probe held at a 90-degree angle to the body and then applying pressure at a constant rate of increasing pressure (30 kPa/s) until the patient's pain threshold is reached. The assessment will be performed bilaterally in 4 different regions, one assessment per anatomical region: trapezius muscle, elbows (lateral epicondyle), quadriceps femoris muscle, and knees (in the medial fat pad near the joint line). For each participant, the total mean pressure pain threshold measurements will be calculated and used for analysis. Sensitive points will be determined according to the guidelines of Okifuji et al. Previous studies have shown that assessing pressure pain threshold measurements in a limited number of regions provides a good estimate of overall sensitivity.
Time frame: At baseline (Day 1)
Cognitive Exercise Therapy Approach Scale
The Cognitive Exercise Therapy Approach Scale assesses the biopsychosocial status of patients with rheumatic diseases. The total score ranges from 0 to 120. Higher scores indicate a worse biopsychosocial status.
Time frame: At baseline (Day 1)
Tampa Kinesiophobia Scale
The original Tampa Kinesiophobia Scale was developed by Miller, Kopri and Todd in 1991, but was not published. Vlaeyen et al. republished the original scale, consisting of 17 questions, in 1995, with the permission of the researchers who developed it. TAS is a 17-question scale developed to measure fear of movement/re-injury. The scale includes injury/re-injury and fear-avoidance parameters in work-related activities.
Time frame: At Baseline (Day 1)
Pain Catastrophizing Scale:
Developed to identify patients' catastrophic thoughts or feelings about the pain they experience and their ineffective coping strategies, this scale is a thirteen-item Likert-type self-assessment scale. Each item is scored between 0 and 4. The total score ranges from 0 to 52. Higher scores indicate a high level of catastrophizing.
Time frame: At baseline (Day 1)
The Short Pain Inventory
The Short Pain Inventory is a short, easy-to-administer assessment method that can be used to evaluate pain. It includes numerical rating scales from 0 to 10. In the Short Pain Inventory, the worst pain is defined as mild (1-4), moderate (5-6), and severe (7-10). It assesses the severity of pain, its localization, medical treatments for pain, and its impact on daily functions, and asks how much pain has decreased in the last 24 hours or the past week. Answering all questions takes a short time, approximately 5-10 minutes.
Time frame: At baseline (Day 1)
Generalized Pain Index and Symptom Severity Scale
The Generalized Pain Index is an index that assesses a patient's pain in 19 regions over the past week. The Symptom Severity Scale consists of 3 questions: fatigue, difficulty thinking and remembering, and sleeplessness. The severity of each of these 3 complaints over the past week is scored using a scale from 0: no problem, 1: mild problem, 2: moderate problem, 3: severe problem.
Time frame: At baseline (Day 1)
Started May 2026 (actual). Primary completion is estimated for Aug 2027, 15 months after the start.
Of 81 non-industry observational studies under Fibromyalgia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 109. This study's planned 15 months is below that.
Counting every sponsor, half of 88 studies reached it within 27 months; a quarter within 8 and three quarters within 91.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zülal TATAR